Why Your Supplements Might Be Working Against Your DNA

The modern biohacker is information-rich and often biochemically confused. They listen to the right podcasts, read abstracts, and spend meaningful money on high-quality supplements. They're also, frequently, supplementing for someone with a completely different genome.

This is not a criticism of the effort. It's a structural problem with how supplement advice is produced and consumed. Almost every recommendation you've read, from a clinical study, a functional medicine protocol, or a longevity podcast, was optimised for a population median. And the population median is a statistical abstraction. Nobody actually lives there.

The population average problem

Clinical trials enroll participants, measure outcomes, and report results averaged across the cohort. When a study concludes that "400mg of magnesium glycinate improves sleep quality," what it's actually reporting is that 400mg produced a statistically significant average improvement across the population studied, which includes people with fast-twitch muscle phenotypes, people with GAD1 variants affecting GABA synthesis, people with low dietary magnesium, and people with none of these factors. The recommendation that emerges collapses all of that heterogeneity into a single number.

For the fraction of people whose biology closely matches the population average, the recommendation works reasonably well. For everyone else, which is, by definition, most people, it's a starting approximation at best. The question your genetics can answer is: how far does your biology deviate from that average, and in which direction?

Three ways your supplement stack can work against your genetics

1. You're supplementing a pathway that's already upregulated

CBS (cystathionine beta-synthase) upregulation is a useful example. CBS is the enzyme that diverts homocysteine down the transsulfuration pathway, converting it into cystathionine and eventually cysteine, taurine, and glutathione. If you carry a CBS upregulation variant, this enzyme already runs at higher-than-normal activity, pulling homocysteine into the sulfur pathway faster than the average person.

Now consider the standard MTHFR protocol: high-dose methylfolate and methylcobalamin to drive methylation and reduce homocysteine via the methionine cycle. For most MTHFR carriers, this makes sense. For someone with concurrent CBS upregulation, you may be pushing more homocysteine into a pathway that's already running fast, creating downstream accumulation of sulfur metabolites, ammonia-adjacent compounds, and disruption of taurine and hydrogen sulfide regulation. The supplement that's correct for a standard MTHFR presentation is genuinely problematic for someone with both variants.

2. You're using a form your receptor can't respond to efficiently

VDR (Vitamin D receptor) variants affect how efficiently your cells respond to Vitamin D signalling, entirely independently of your serum 25-OH-D level. The VDR Bsm1 polymorphism (rs1544410) is associated with altered receptor transcriptional activity, which means that two people with identical serum Vitamin D levels may have substantially different intracellular signalling outcomes in immune function, bone metabolism, and inflammatory regulation.

A VDR Bsm1 bb homozygote may maintain "adequate" serum Vitamin D at 75nmol/L while experiencing blunted downstream effects that would only be apparent if you looked past the blood marker and at their symptom picture and genotype together. Standard dosing recommendations built around serum levels assume average receptor sensitivity. If your receptor is less responsive, maintaining the same serum level may require different intake to achieve equivalent physiological effect, or the clinical situation doesn't resolve despite apparently normal lab values.

3. You're clearing a compound too fast, or not fast enough

CYP1A2 is the cytochrome P450 enzyme responsible for approximately 95% of caffeine metabolism. Fast CYP1A2 metabolisers clear caffeine efficiently; slow metabolisers accumulate it. This matters beyond tolerance: slow metabolisers consuming high caffeine intake show elevated risk of non-fatal myocardial infarction in several epidemiological studies, a risk not observed in fast metabolisers at equivalent doses. Same compound, same dose, meaningfully different outcome based on genotype alone.

COMT genotype shows the same pattern with catecholamines. A COMT Val/Val carrier (fast clearance) and a COMT Met/Met carrier (slow clearance) will have substantially different responses to the same nootropic stack, the same methylation protocol, and the same stimulant or adaptogen. Compounds that are well-tolerated and effective for one may cause anxiety, mood instability, or diminishing returns for the other, not because of dosing error, but because the metabolic pathway handling the compound runs at different rates.

What building a protocol correctly looks like

The correct approach is to start with what your genome is telling you about your actual bottlenecks, not to reverse-engineer a genetic justification for a supplement stack you already believe in. That means identifying which pathways are genuinely impaired by your variants, which are compensated or upregulated, and what the evidence base says about the magnitude of effect in people who carry your specific profile.

It also means accepting that some of what you're currently taking is probably doing nothing, and some of it may be working against you. That's uncomfortable information. It's also the only honest foundation for a protocol that actually performs.

The biohacking community has done a genuinely useful thing in making genomic literacy more mainstream. The next step is using that literacy more precisely, not just knowing which variants you carry, but understanding how they interact and what the evidence says about intervening on them specifically.

Want this applied to your actual variant profile?

Get My DNA Report · $297 →